The role of relapse prevention for depression in collaborative care: A systematic review.

Chronic Disease Depression / prevention & control Humans Primary Health Care Recurrence Secondary Prevention
Collaborative care Depression Relapse prevention

Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
15 03 2020
Historique:
received: 19 04 2019
revised: 01 10 2019
accepted: 21 11 2019
pubmed: 4 12 2019
medline: 16 2 2021
entrez: 4 12 2019
Statut: ppublish

Résumé

Relapse (the re-emergence of depression symptoms before full recovery) is common in depression and relapse prevention strategies are not well researched in primary care settings. Collaborative care is effective for treating acute phase depression but little is known about the use of relapse prevention strategies in collaborative care. We undertook a systematic review to identify and characterise relapse prevention strategies in the context of collaborative care. We searched for Randomised Controlled Trials (RCTs) of collaborative care for depression. In addition to published material, we obtained provider and patient manuals from authors to provide more detail on intervention content. We reported the extent to which collaborative care interventions addressed four relapse prevention components. 93 RCTs were identified. 31 included a formal relapse prevention plan; 42 had proactive monitoring and follow-up after the acute phase; 39 reported strategies for optimising sustained medication adherence; and 20 of the trials reported psychological or psycho-educational treatments persisting beyond the acute phase or focussing on long-term health/relapse prevention. 30 (32.3%) did not report relapse prevention approaches. We did not receive trial materials for approximately half of the trials, which limited our ability to identify relevant features of intervention content. Relapse is a significant risk amongst people treated for depression and interventions are needed that specifically address and minimise this risk. Given the advantages of collaborative care as a delivery system for depression care, there is scope for more consistency and increased effort to implement and evaluate relapse prevention strategies.

Sections du résumé

BACKGROUND
Relapse (the re-emergence of depression symptoms before full recovery) is common in depression and relapse prevention strategies are not well researched in primary care settings. Collaborative care is effective for treating acute phase depression but little is known about the use of relapse prevention strategies in collaborative care. We undertook a systematic review to identify and characterise relapse prevention strategies in the context of collaborative care.
METHODS
We searched for Randomised Controlled Trials (RCTs) of collaborative care for depression. In addition to published material, we obtained provider and patient manuals from authors to provide more detail on intervention content. We reported the extent to which collaborative care interventions addressed four relapse prevention components.
RESULTS
93 RCTs were identified. 31 included a formal relapse prevention plan; 42 had proactive monitoring and follow-up after the acute phase; 39 reported strategies for optimising sustained medication adherence; and 20 of the trials reported psychological or psycho-educational treatments persisting beyond the acute phase or focussing on long-term health/relapse prevention. 30 (32.3%) did not report relapse prevention approaches.
LIMITATIONS
We did not receive trial materials for approximately half of the trials, which limited our ability to identify relevant features of intervention content.
CONCLUSION
Relapse is a significant risk amongst people treated for depression and interventions are needed that specifically address and minimise this risk. Given the advantages of collaborative care as a delivery system for depression care, there is scope for more consistency and increased effort to implement and evaluate relapse prevention strategies.

Identifiants

DOI: 10.1016/j.jad.2019.11.105 PMID: 31791677
pubmed: 31791677
pii: S0165-0327(19)30734-7
doi: 10.1016/j.jad.2019.11.105
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

618-644

Subventions

Organisme : Medical Research Council
ID : G0701013
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Andrew S Moriarty (AS)

Department of Health Sciences and the Hull York Medical School, University of York, Heslington, York, YO10 5DD, UK. Electronic address: andrew.moriarty@york.ac.uk.

Peter A Coventry (PA)

Department of Health Sciences and Centre for Reviews and Dissemination, University of York, Heslington, York, YO10 5DD, UK. Electronic address: peter.coventry@york.ac.uk.

Joanna L Hudson (JL)

King's College London, Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, 16 De Crespigny Park, London, SE5 8AF, UK. Electronic address: joanna.hudson@kcl.ac.uk.

Natalie Cook (N)

Department of Health Sciences and the Hull York Medical School, University of York, Heslington, York, YO10 5DD, UK. Electronic address: natalie.cook@york.ac.uk.

Oliver J Fenton (OJ)

Tees, Esk and Wear Valleys NHS Foundation Trust, South and West Community Mental Health Team, Acomb Garth, 2 Oak Rise, York, YO24 4LJ, UK. Electronic address: ojfenton@gmail.com.

Peter Bower (P)

NIHR School for Primary Care Research, Centre for Primary Care, Manchester Academic Health Science Centre, University of Manchester, Oxford Rd, Manchester, M13 9PL, UK. Electronic address: peter.bower@manchester.ac.uk.

Karina Lovell (K)

Division of Nursing, Midwifery & Social Work, University of Manchester, Oxford Rd, Manchester, M13 9PL, UK. Electronic address: karina.lovell@manchester.ac.uk.

Janine Archer (J)

School of Health and Society, University of Salford, Mary Seacole Building, Broad St, Frederick Road Campus, Salford, M6 6PU, UK. Electronic address: j.e.archer@salford.ac.uk.

Rose Clarke (R)

Sheffield IAPT, St George's Community Health Centre, Winter Street, Sheffield, South Yorkshire, S3 7ND, UK. Electronic address: rosecclarke@gmail.com.

David A Richards (DA)

Institute of Health Research, College of Medicine and Health, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK. Electronic address: d.a.richards@exeter.ac.uk.

Chris Dickens (C)

Institute of Health Research, College of Medicine and Health, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK. Electronic address: c.m.dickens@exeter.ac.uk.

Linda Gask (L)

NIHR School for Primary Care Research, Centre for Primary Care, Manchester Academic Health Science Centre, University of Manchester, Oxford Rd, Manchester, M13 9PL, UK. Electronic address: linda.gask@manchester.ac.uk.

Waquas Waheed (W)

NIHR School for Primary Care Research, Centre for Primary Care, Manchester Academic Health Science Centre, University of Manchester, Oxford Rd, Manchester, M13 9PL, UK. Electronic address: waquas.waheed@manchester.ac.uk.

Klaas M Huijbregts (KM)

GGNet, Mental Health, RGC SKB Winterswijk, Beatrixpark 1, 7101 BN Winterswijk, The Netherlands. Electronic address: k.huijbregts@ggnet.nl.

Christina van der Feltz-Cornelis (C)

Department of Health Sciences and the Hull York Medical School, University of York, Heslington, York, YO10 5DD, UK. Electronic address: christina.vanderfeltz-cornelis@york.ac.uk.

Shehzad Ali (S)

Epidemiology and Biostatistics Department, Schulich School of Medicine & Dentistry, Western University, Kresge Building, Room K201, London, Ontario, N6A 5C1, Canada; Department of Health Sciences, University of York, Heslington, York, YO10 5DD, UK. Electronic address: shehzad.ali@uwo.ca.

Simon Gilbody (S)

Department of Health Sciences and the Hull York Medical School, University of York, Heslington, York, YO10 5DD, UK. Electronic address: simon.gilbody@york.ac.uk.

Dean McMillan (D)

Department of Health Sciences and the Hull York Medical School, University of York, Heslington, York, YO10 5DD, UK. Electronic address: dean.mcmillan@york.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › The role of relapse prevention for depression...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Émotions › Dépression › The role of relapse prevention for depression...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The role of relapse prevention for depression...
questionsmedicales.fr › Administration des services de santé › Gestion des soins aux patients › Services de santé polyvalents › Soins de santé primaires › The role of relapse prevention for depression...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Récidive › The role of relapse prevention for depression...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention secondaire › The role of relapse prevention for depression...